Neurologic Disorder
Conditions
Brief summary
Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.
Interventions
DRUGPerampanel
Efficacy of epilepsy drugs
Sponsors
National Taiwan University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients under 18 years of age suffering from epilepsy * Patients who are taking Paraampanel
Exclusion criteria
* Patients who are not in the above age groups and who are not using parampanel
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The efficacy of perampanel in young children with drug-resistant epilepsy | 17 years | Because the current clinical research data on the use of Fycompa (perampanel) in children for the treatment of epilepsy is still insufficient, the purpose of this research is to review the efficacy of this drug in the treatment of children with epilepsy in our hospital in the past, so as to facilitate the future clinical treatment of children with epilepsy. Children have the possibility of therapeutic reference. |
Countries
Taiwan
Outcome results
None listed